Novel substituted azabenzoxazoles

A method of inhibiting MAO-B activity in a mammal, comprising administering an effective amount of a compound of formula I

• or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof,
• wherein:
• X is O or S;
• A and Y independently are N, or CH;
• Z is selected from the group consisting of phenyl, benzothiazolyl, indolyl, pyridyl, pyrazolopyridinyl, benzodioxolyl, and pyrrolopyridinyl all optionally substituted with 1 to 3 groups of R2, R3 or R4;
• R represents hydrogen, or —C1-6alkyl;
• R1 represents hydrogen, —C5-10 heterocyclyl, —N(R2)2, CN, —(CH2)nhalo, CF3, —O(CH2)nR, —O(CH2)nC5-10 heterocyclyl, —C1-6alkyl, —OCF3, —O(CH2)nF, —(O(CH2)s)phalo, —(O(CH2)s)pOR, —C(O)OR, or hetero-spirocycle said alkyl, and heterocyclyl optionally substituted with 1 to 3 groups of Ra,
• R2, R3 and R4 independently represent hydrogen, —(CH2)nhalo, —C1-6alkyl, —CF3, (CH2)nOR, (CH2)nC5-10 heterocyclyl, —N(R)2, said alkyl, and heterocyclyl optionally substituted with 1 to 3 groups of Ra;
• Ra represents —CN, NO2, halo, CF3, —C1-6alkyl, —C1-6alkenyl, —(CH2)nhalo, —OR, —NRR1, —C(═NR1)NR2R3, —N(═NR1)NR2R3, —NR1COR2, —NR1CO2R2, —NR1SO2R4, —NR1CONR2R3, —SR4, —SOR4, —SO2R4, —SO2NR1R2, —COR1, —CO2R1, —CONR1R2, —C(═NR1)R2, or —C(NOR1)R2;
• n represents 0-6;
• s represents 2-4;
• and
• p represents 1-3
• and measuring the effect of the compound on MAO-B activity in the patient.